Biomarker Services

deep expertise • flexible solutions • close collaboration • rapid delivery

End‑to‑End Biomarker Strategy for Drug Discovery

At Domainex, we offer an integrated, end‑to‑end biomarker discovery and translational assessment capability that supports drug discovery from early identification through to preclinical decision‑making. Our comprehensive suite of technologies, combined with Human Tissue Act accreditation enabling access to primary human cells from healthy and disease state donors, ensures biologically meaningful and clinically relevant insights from the start.

 

Whether you require a hypothesis‑driven strategy or an unbiased multi‑omics approach, our experts deliver high‑quality biomarker data to guide target validation, lead optimisation and translational confidence.

 

 

Integrated Biomarker Workflow at Domainex

1. Biomarker Identification

Domainex apply state‑of‑the‑art discovery platforms to identify robust, mechanism‑linked biomarkers that inform target engagement and pathway modulation.

Target Expression and Validation

  • RNA‑seq for unbiased target discovery
  • Agnostic readout identification
  • qPCR for targeted confirmation

Metabolic and Functional Readouts

  • LC‑MS‑based metabolomics to detect pathway‑level metabolic changes
  • Functional metabolic profiling to link compound activity to mechanism

Pathway Modulation and Signalling Biology

  • Whole‑proteome and focused‑panel proteomics (LC‑MS)
  • ELISA, AlphaLISA and automated Western blotting
  • Quantification of pathway engagement and downstream effects

Deep Immune Phenotyping

  • High‑parameter spectral flow cytometry
  • Detection of pharmacodynamic responses in rare or low‑frequency immune subsets

2. Biomarker Evaluation​

Domainex scientists rigorously evaluate biomarkers to confirm pharmacology, define dose–response relationships and understand duration of action.

Mechanism‑Driven Pharmacology

  • Disease‑relevant models using primary human cells, sorted immune cell populations and whole blood
  • Expert immunologists and cell biologists ensuring physiologically relevant outcomes

 

Advanced Cell Isolation Capabilities

  • Magnetic bead‑based enrichment
  • High‑purity fluorescence‑activated cell sorting (FACS)
  • Enabling cell‑specific biomarker assessment and downstream analysis

3. Translational Assessment

Domainex scientists design biomarker programmes with translation in mind, ensuring continuity from in vitro discovery to in vivo model systems.

Quantitative Measurement Across Matrices

  • Biomarker analysis in whole blood, plasma, tissues and isolated cell subsets
  • LC‑MS–based quantitative bioanalysis for sensitivity and reproducibility
  • Hybrid immunopurification–MS workflows enabling detection of low‑abundance biomarkers

Preclinical Translation

  • Alignment of in vitro and in vivo biomarker strategies
  • Support for PK/PD modelling and candidate selection
  • De‑risking progression into preclinical and early‑clinical development

Why Domainex for Biomarker Services?

 

Expert, multidisciplinary team

At Domainex, immunologists, cell biologists and analytical scientists work together under one roof, bringing deep expertise across proteomics, metabolomics, spectral and traditional flow cytometry, cellular assays and translational pharmacology. This integrated environment ensures efficiency and speed while maintaining scientific rigour at every stage.

 

Flexible, collaborative approach

Every programme is unique. Domainex scientists design bespoke workflows tailored to your scientific objectives and adapt rapidly as new insights emerge, keeping your project moving efficiently and effectively.

 

Translational focus

The team at Domainex are able to evaluate biomarkers in whole blood, PBMCs, isolated immune cell subsets, physiologically relevant cellular systems and in vivo models to ensure the biomarkers we identify are robust, clinically meaningful and decision‑enabling.

Frequently Asked Questions

What biomarker services does Domainex offer?

Domainex provides end‑to‑end biomarker discovery and translational support, covering discovery, evaluation, and quantitative measurement across in vitro and in vivo studies.

Core service areas include:

  • Biomarker discovery (RNA‑seq, proteomics, metabolomics)
  • Targeted biomarker validation (qPCR, immunoassays, Western blotting)
  • Cell‑based pharmacology and mechanism‑of‑action studies
  • Immune profiling and rare‑cell analysis
  • Quantitative LC‑MS and hybrid immunopurification–MS bioanalysis
  • PK/PD‑linked biomarker assessment
  • Custom assay development
  • Translational biomarker strategy design
What technologies does Domainex use?

Domainex applies a broad suite of multi‑omics and analytical platforms to identify and measure biomarkers.

Key technologies include:

  • RNA‑seq for unbiased biomarker discovery
  • qPCR for targeted gene expression confirmation
  • LC‑MS proteomics and metabolomics
  • ELISA, AlphaLISA, and automated Western blotting
  • High‑parameter spectral flow cytometry
  • Magnetic bead enrichment and FACS for cell isolation
  • Hybrid immunopurification–mass spectrometry for low‑abundance biomarkers
What types of biomarkers can Domainex measure?

Domainex can quantify a wide range of biomarker classes.

Biomarker types include:

  • Gene expression markers
  • Protein biomarkers
  • Cytokines and chemokines
  • Metabolic biomarkers
  • Pathway‑specific signalling markers
  • Cell‑surface markers
  • Immune activation and suppression markers
  • Low‑abundance biomarkers requiring enhanced sensitivity
Can Domainex work with primary human cells?

Yes. Domainex is Human Tissue Act accredited, enabling work with primary human cells from healthy and disease‑state donors to ensure translational relevance.

Primary cell capabilities include:

  • Access to healthy and disease‑state donor cells
  • Isolation of specific immune subsets
  • Use of primary cells in pharmacology and biomarker assays
  • Enhanced translational relevance for early‑stage programmes
Does Domainex support immune related biomarker studies?

Yes. Domainex has strong immunology expertise.

Immune biomarker capabilities include:

  • High‑parameter spectral flow cytometry
  • Rare‑cell population analysis
  • Cytokine and chemokine profiling
  • Immune activation and suppression readouts
  • Mechanism‑of‑action studies in immune cells
What sample types can be analysed?

Biomarkers can be measured in:

  • Whole blood
  • Plasma and serum
  • Tissue samples
  • Isolated immune cell subsets
  • Primary human cells
  • Disease‑relevant cell models
What cell based biomarker assays can Domainex perform?

Domainex offers a wide range of functional and phenotypic assays.

Cell‑based assay capabilities include:

  • Target engagement assays
  • Phenotypic screening
  • Cytokine release assays
  • Protein expression and signalling pathway analysis
  • Metabolic profiling
  • Cell viability and proliferation assays
  • Custom assay development for specific pathways
How does Domainex ensure biomarker data is translationally relevant?

Domainex integrates biomarker work into broader drug discovery workflows.

Translational strengths include:

  • Alignment of in vitro and in vivo biomarker strategies
  • Use of primary human cells
  • PK/PD biomarker modelling support
  • Mechanism‑driven assay design
  • Quantitative LC‑MS for precise biomarker measurement
Does Domainex offer custom biomarker assay development?

Yes, Domainex can design, optimise, and validate bespoke assays.

Custom assay options include:

  • Immunoassays (ELISA, AlphaLISA)
  • LC‑MS and hybrid MS workflows
  • Cell‑based functional assays
  • Gene expression assays
  • Pathway‑specific biomarker panels
Does Domainex support translational and PK/PD biomarker studies?

Yes. Biomarker data is integrated into PK/PD models to support dose selection, mechanism confirmation, and candidate progression from early discovery through preclinical development.

Does Domainex support biomarker studies linked to GPCR and fibrosis biology?

Yes. Domainex’s biomarker services integrate directly with its GPCR and fibrosis biology platforms to support mechanism‑driven research.

GPCR biology:

  • Biomarkers linked to GPCR activation or inhibition
  • Second‑messenger readouts (e.g., cAMP, Ca²⁺)
  • Pathway‑specific gene/protein expression
  • Functional assays in GPCR‑expressing systems

Fibrosis biology:

  • Biomarkers of fibroblast activation and ECM remodelling
  • Cytokine/chemokine profiling
  • TGF‑β‑related gene expression markers
  • Cell‑based fibrosis models for translational biomarker assessment
What makes Domainex’s biomarker offering distinctive?
  • Integrated discovery‑to‑translation workflow
  • Multi‑omics capability in one location
  • Expertise in immunology, cell biology, and bioanalysis
  • Ability to detect low‑abundance biomarkers
  • Access to primary human cells
  • Custom assay development tailored to each programme
  • Strong track record across therapeutic areas
What makes Domainex a strong partner for biomarker research?

Domainex offers:

  • Flexibility - fully customisable assay design
  • Deep scientific expertise in biomarker discovery
  • Collaborative partnership - acting as an extension of your R&D team
  • Rapid turnaround - enabling faster decision‑making and preclinical progression